Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $549000.0.

  • Protalix BioTherapeutics' Other Non-Current Assets fell 213.9% to $549000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $549000.0, marking a year-over-year decrease of 213.9%. This contributed to the annual value of $462000.0 for FY2024, which is 1250.0% down from last year.
  • Protalix BioTherapeutics' Other Non-Current Assets amounted to $549000.0 in Q3 2025, which was down 213.9% from $520000.0 recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Other Non-Current Assets peaked at $2.1 million during Q4 2021, and registered a low of $459000.0 during Q1 2025.
  • Its 5-year average for Other Non-Current Assets is $1.1 million, with a median of $1.3 million in 2023.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 1885.3% in 2021, then tumbled by 5832.68% in 2023.
  • Protalix BioTherapeutics' Other Non-Current Assets (Quarter) stood at $2.1 million in 2021, then crashed by 39.0% to $1.3 million in 2022, then plummeted by 58.33% to $528000.0 in 2023, then fell by 12.5% to $462000.0 in 2024, then rose by 18.83% to $549000.0 in 2025.
  • Its last three reported values are $549000.0 in Q3 2025, $520000.0 for Q2 2025, and $459000.0 during Q1 2025.